You just read:

Data from Rebiotix's Phase 2b Trial of Lead Microbiota-Based Drug Candidate, RBX2660, to be Featured in Late-Breaking Oral Presentation at UEG Week 2016

News provided by

Rebiotix Inc.

Oct 17, 2016, 09:39 ET